The bone is a preferred site for metastatic homing of prostate cancer cells. Once prostate cancer patients develop skeletal metastases, they eventually succumb to the disease; therefore, it is imperative to identify key molecular drivers of this process. This study examines the involvement of protein kinase C epsilon (PKCε), an oncogenic protein that is abnormally overexpressed in human tumor specimens and cell lines, on prostate cancer cell bone metastasis.
INTRODUCTION
Prostate cancer is the second leading cause of cancer-related deaths among men, with ~221,000 new cases and ~27,500 deaths estimated for 2015 in the United States, according to the American Cancer Society. The majority of prostate cancer related deaths results from metastatic spread of prostate cancer cells from the primary tumor to contiguous and distal sites. One of the preferred sites of metastatic dissemination of prostate cancer cells is the bone. Once the disease reaches this advance stage it becomes inevitably fatal, as 5-year survival for prostate cancer patients with skeletal involvement is <1%. The bone metastatic process first involves the detachment and shedding of cancer cells from the primary tumor into a blood vessel, an event called intravasation, followed by hematogenous dissemination and homing to specific niches in the bone, particularly perivascular niches of the bone marrow sinusoids where active metastatic foci form (1) . The molecular mechanisms implicated in prostate cancer cell metastasis are poorly understood, which ultimately limits the development of effective therapies aimed at preventing the spread of prostate cancer cells and formation of secondary skeletal metastasis in patients.
The PKC serine-threonine kinases have been broadly implicated in the regulation of signaling pathways that control cell proliferation, differentiation, apoptosis and motility. This kinase family comprises 10 structurally related isozymes that have been classified into 3 different groups with diverse biochemical and functional properties: "classical/conventional" cPKCs (α, βI, βII, and γ), "novel" nPKCs (δ, ε, η, and θ), and "atypical" aPKCs (ζ and λ/ι). cPKCs and nPKCs are established cellular receptors for the phorbol ester tumor promoters, and at a physiological level they become activated by the lipid second messenger diacylglycerol (DAG). Although PKCs have been widely implicated in tumor promotion, it is now recognized that individual isozymes have distinctive roles in the progression of cancer, both in positive and negative manners (2) (3) (4) . Among the different members of the PKC family, numerous studies in the last years unambiguously established PKCε as an oncogenic kinase and tumor biomarker (5, 6) . Notably, PKCε is markedly up-regulated in epithelial cancers, including prostate, lung, breast, and head and neck cancer (2, (7) (8) (9) (10) (11) (12) . In lung and breast cancer cells, silencing PKCε expression using RNAi impairs their ability to grow as xenografts in nude mice (7, 12, 13) .
These results have been validated pharmacologically with specific PKCε inhibitors (12, 13) , thus highlighting the importance of this kinase in the maintenance of tumor growth. In addition to its 4 role in tumorigenesis, numerous reports linked PKCε to metastatic dissemination. For example, NIH 3T3 cells constitutively expressing PKCε develop invadopodial-like structures, exhibit increased pericellular metalloprotease activity, and display metastatic capacity in nude mice (14) .
Moreover, PKCε is required for motility and invasion in various cancer cellular models in culture as well as for metastatic dissemination in vivo. Most remarkably, studies using transgenic PKCε mice established this kinase as a driver of metastatic skin squamous cell carcinoma (15) (16) (17) (18) (19) .
PKCε is barely detected in normal or benign human prostatic epithelium, whereas it is highly expressed in prostate tumors and in recurrent disease. Nearly 100% of human prostate tumors overexpress PKCε, particularly advanced metastatic tumors (10, 15, 20, 21) .
Accordingly, androgen-independent prostate cancer cells display significant PKCε up-regulation relative to androgen-dependent prostate cancer cell lines or "normal" immortalized prostate epithelial cells, and ectopic expression of PKCε in androgen-dependent prostate cancer cells contributes to the acquisition of androgen independence (22, 23) . In an in vivo context, our laboratory showed that transgenic overexpression of PKCε in the mouse prostate leads to the formation of preneoplastic lesions (23, 24) . Moreover, in the transgenic mouse model of prostate adenocarcinoma (TRAMP), genetic ablation of PKCε inhibits the development of prostate cancer and spontaneous metastatic dissemination to lymph nodes, lung, and kidney (17) . Regardless of the distinctive roles assigned to PKCε in different stages of disease progression, the role of PKCε in the dissemination of prostate cancer cells to the bone remains elusive.
In this study, we investigated whether PKCε could play a role in the formation of skeletal tumors in mice. We took advantage of PC3-ML cells, a subline derived from the widely used PC3 cell line that consistently produces skeletal metastasis in mice (25, 26) . We present for the first time evidence that PKCε mediates the invasive capacity of these cells and is required for the formation of skeletal tumors in mice.
MATERIALS AND METHODS

Cell culture
PC3-ML cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. HUVEC cells were purchased from Lonza (Walkersville, MD) and cultured in EGM-2-BulletKit medium (Lonza), as indicated by the provider. MG-63 osteosarcoma cells were purchased from ATCC and cultured in DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. The PKCε inhibitor εV1-2 (tat-fused) and its control peptide Tat were a kind gift from Dr. Daria Mochly-Rosen (Stanford University).
Lentiviral infections
Stable depletion of PKCε in PC3-ML cells was achieved by infection with shRNA lentiviruses (MISSION® shRNA Lentiviral Transduction particles, Sigma, St Louis, MO). As a control we used the MISSION® non-target shRNA lentivirus. Selection of stable cell lines was carried out with puromycin (0.3 μg/ml, 3 weeks).
Western blot assays
Western blots and densitometric analyses were carried out as previously described (27) .
The following antibodies (1:1000 dilution) were used: anti-PKCε (sc-214; Santa Cruz Biotechnology, Dallas, TX), anti-Rac1 (05-389; Upstate Biotechnology, Billerica, MA), antiinterleukin-1β (sc-1251; Santa Cruz Biotechnology, Dallas, TX), and anti-vinculin (V9131 Sigma). Bands were visualized by the enhanced chemiluminescence (ECL) Western blotting detection system. Images were captured using a FUJIFILM LAS-3000 system and the LAS-2000 software.
Cell growth assays
Cells (1 x 10 5 ) were seeded onto 96-well plates. At different times, cell viability in triplicate samples was determined with the CellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI), as previously described (28) .
Migration and invasion assays
Cells were trypsinized, suspended in 0.1% BSA/RPMI, and seeded (1.5 x 10 4 cells/well) in the upper compartment of a Boyden chamber (NeuroProbe, Gaithersburg, MD). Polycarbonate membranes of 12 µM pore diameter were used to separate the upper and lower compartments. In the lower chamber, RPMI medium containing 10% FBS was used. After an incubation period of 18 h at 37°C, membranes were recovered and cells on the upper side (non-migratory) were wiped off the surface. Cells on the lower side of the membrane were fixed and stained with the DIFF Quik Stain Set (Dade Behring, Deerfield, IL). Migratory cells in each well were counted by contrast microscopy in 5 random fields. Invasion assays were carried out in Boyden chambers using Matrigel-coated polycarbonate membranes, as previously described (18) . For some assays, we preincubate cells with IL-1β (10 nM, R&D Systems, Minneapolis, MN), or incubate them with anti-IL-1β blocking antibody (1 μM, R&D Systems) or control IgG (Santa Cruz Biotechnology, Dallas, TX).
Rac-GTP pull-down assays
Determination of Rac-GTP levels was carried out essentially as previously described (28) . Briefly, cells growing at 80% confluency were lysed in pull-down buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl 2 , 0.5% NP40, 5 mM β-glycerophosphate, 1 mM DTT, and protease inhibitors) containing 15 µg/ml of PBD-GST. Lysates were cleared by centrifugation (10 min at 4°C, 13,000 x g) and incubated with glutathione-Sepharose 4B beads (GE Healthcare, Buckinghamshire, UK) for 45 min at 4°C. After centrifugation, the beads were washed twice with pull-down buffer and run on SDS-PAGE. Rac1 in the beads (Rac1-GTP) was detected by Western blot using an anti-Rac1 antibody.
Adhesion assays
Plates were coated with 500 μg/ml collagen, poly-L-lysine, or Matrigel, and blocked with 0.5% BSA. Cells (3 x 10 4 cells/well in 0.1% BSA/RPMI) were seeded in triplicate. FBS (10%) was added to stimulate adhesion. After incubation at 37°C for different times, unattached cells were washed with PBS. Attached cells were fixed and stained with DAPI. Plates were visualized by fluorescence microscopy, and the number of nuclei from attached cells was quantified in 5 random fields cells using the ImageJ software.
Quantitative real-time PCR (qPCR)
For the determination of IL-1β and PKCε mRNA levels, total RNA was extracted from subconfluent cell cultures using the RNeasy kit (Qiagen, Valencia, CA). One μg of RNA from each sample was reverse transcribed using the TaqMan reverse transcription reagent kit (Applied Biosystems, Branchburg, NJ) with random hexamers used as primers. PCR primers and 5'-end 6-carboxyfluorescein-labeled probes for PKCε and IL-1β were purchased from Applied Biosystems. PCR was performed using an ABI PRISM 7700 detection system in a total volume of 25 μl containing TaqMan universal PCR MasterMix (Applied Biosystems), commercial target primers (300 nM), the fluorescent probe (200 nM), and 1 μl cDNA. PCR product formation was continuously monitored using the sequence detection system software version 1.7 (Applied Biosystems) (29) . The 6-carboxyfluorescein signal was normalized to endogenous tRNA 18S.
ΔCt was obtained by subtracting the cycle threshold (CT) of 18S or ubiquitin C from that of PKCε. Δ(ΔCt) was determined by subtracting the control ΔCt from the sample ΔCt. Foldchanges were calculated using Data Assist software from Life Technologies, and expressed as 2
. mRNA levels for 84 invasive and metastatic genes, including extracellular matrix (ECM) proteases and protease inhibitors, were determined by qPCR using the Human Tumor Metastasis RT2 Profiler PCR Array and a RT2 SYBR Green/5-carboxy-X-rhodamine (ROX) qPCR master mix (Qiagen). Data were normalized using ACTB, GAPDH, B2M, HPRT1, and RPLP0 housekeeping genes provided in the PCR array. The relative mRNA levels were calculated using the ∆∆CT method, as indicated in the RT2 Profiler PCR Array Data Analysis Webportal.
Tumor growth and bone metastasis in nude mice
Studies were carried out in strict accordance with the recommendations from the Guide Bone metastasis experiments were carried out essentially as previously described (26, 30) . Briefly, PC3-ML cell lines were infected with ZsGreen Lentivirus, which had been produced using Lenti-X high-titer lentiviral packaging systems (Lenti- 
Bone marrow cultures
Bone marrow from mouse tibia and femur were flushed after 3 weeks after intracardiac inoculation. Cells were dissociated using a syringe (19G needle) and incubated with RPMI media supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.3 μg/ml puromycin. After 7 days in culture, the presence of ZsGreen fluorescent colonies was determined using an inverted microscope. 
Transendothelial assays
We used the in vitro assay described by Okada et al. (31) To determine adhesion to endothelial cells, PC3-ML cells were labeled with
[³H]thymidine (1 mCi) for 18 h. Labeled PC3-ML cells were centrifuged and resuspended in 2.5 ml of RPMI, and 100 μl of this suspension were added to 24-well plates that had been previously seeded with HUVEC cells (100% confluency). After 30 or 60 min, non-adherent PC3-ML cells were removed by washing three times with 250 μl PBS. The remainder was lysed with 250 μl 0.1 M NaOH, and radioactivity counted in a scintillation counter.
Co-culture experiments
Osteoblast co-culture experiments were carried out essentially as described (32) . Briefly, 
RESULTS
PKCε mediates metastasic dissemination of PC3-ML prostate cancer cells to the bone
Emerging data from several laboratories established essential roles for PKCε in the progression of cancer, including prostate cancer (2, 5, 6, 10, 17) . PKCε has been implicated in cell invasiveness, yet it is not clear whether this kinase plays a role in metastasis to the bone, a main site of prostate cancer cell dissemination. To this end, we took advantage of a wellestablished model of experimental metastasis that uses PC3-ML human prostate cancer cells, a cell line with high bone metastatic potential derived from the PC3 parental cell line (25, 26) . As previously reported for parental androgen-independent PC3 and DU145 cells (11, 23) , the PC3-ML subline displays elevated levels of PKCε relative to "normal" immortalized prostate epithelial cells (Fig. 1a) . To ascertain the role of PKCε in prostate cancer bone metastasis, we used shRNA lentiviruses to stably knockdown PKCε from PC3-ML cells, followed by selection with puromycin. Two different shRNA lentiviruses were used (ε1 and ε2) in order to generate PC3-ML-KDε1 and PC3-ML-KDε2 cell lines. As a control, we generated a PC3-ML cell line infected with a non-target control shRNA lentivirus (PC3-ML-NTC). As shown in Fig. 1b , ~ 85% and 70% depletion in PKCε levels was achieved in PC3-ML-KDε1 and PC3-ML-KDε2 cell lines, respectively (n=3).
To address the relevance of PKCε in a metastasis model in vivo, cell lines were engineered to stably express the GFP variant ZsGreen using a lentiviral approach. ZsGreen expression did not significantly affect PKCε levels in PC3-ML cells (Fig. 1a) . Studies showed that upon direct inoculation in the blood circulation of immunodeficient mice, these cells generate metastatic foci primarily in femur and tibia, jaws and ribs (25) . Parental PC3-ML, PC3-ML-NTC, PC3-ML-KDε1 and PC3-ML-KDε2 cells were inoculated in the left cardiac ventricle of athymic nude mice, as previously described (33) . Mice were sacrificed after 3 or 21 days, and their femur and tibiae harvested, fixed, and analyzed for the presence of micrometastasis, as essentially no bone metastatic foci could be detected in the femur/tibia upon injection of PC3-ML-KDε1 and PC3-ML-KDε2 cells (Fig. 1d) .
As a complementary approach, we analyzed bone marrows for the presence of fluorescent ZsGreen labeled cells. Three weeks after intracardiac inoculation of PC3-ML cells into athymic mice, bone marrows from tibiae and femurs were flushed and cultured in vitro.
While a significant number of ZsGreen labeled cells could be detected in bone marrows from mice injected with either parental PC3-ML or PC3-ML-NTC cells, fluorescent cells could not be isolated from bone marrows from mice inoculated with either PC3-ML-KDε1 or PC3-ML-KDε2 cells (Fig. 2) . Thus, PKCε is required for bone metastatic dissemination of PC3-ML cells.
PKCε depletion has limited effects on PC3-ML cell growth, adhesiveness, and motility
PKCε is known to mediate proliferation in a number of cancer cells, such as lung and breast cancer cellular models (12, 13, 16 ). When we examined the effect of silencing PKCε on the growth properties of PC3-ML cells in culture, we noticed only a marginal reduction in cell number in PC3-ML-KDε1 and PC3-ML-KDε2 cells relative to control cell lines (Fig. 3a) .
Similar results were observed when we analyzed the tumorigenic properties of these cells in vivo. Indeed, upon s.c. inoculation into nude mice (1.2 x 10 6 cells), the formation of tumors by PKCε-depleted cell lines was somehow slower, although there were no statistically significant differences between the different cell lines (Fig. 3b) . Similar results were observed in experiments using a higher number of cells (4 x 10 6 cells) (data not shown).
The capacity of cancer cells to successfully metastasize is frequently associated with changes in their adhesive properties and their ability to migrate. We therefore examined the effect of PKCε depletion on the adhesive capacity of PC3-ML cells to different substrates.
These experiments revealed essentially no significant differences in adhesion to Matrigel, collagen or poly-L-lysine coated plates between PKCε-depleted and control PC3-ML cells (Fig.   3c ).
In a recent study using lung cancer models, we showed a critical requirement of PKCε for motile activity. Moreover, we established that PKCε controls the activation of Rac1, a small GTPase widely implicated in cytoskeletal rearrangements and cell migration (18) . Thus, we asked if silencing the expression of PKCε could impair the motility of PC3-ML cells. As Fig. 3d , the ability of PC3-ML cells to migrate, as determined by means of a Boyden chamber assay, remained essentially unchanged as a consequence of PKCε depletion.
PC3-ML cells display constitutively elevated levels of active Rac-GTP levels compared to nontransformed prostate epithelial cells (data not shown). However, and consistent with the lack of involvement of PKCε in PC3-ML cell migration, silencing PKCε fails to reduce Rac-GTP levels in this cell line (Fig. 3e) .
PKCε is required for PC3-ML cell invasiveness: a role for IL-1β
In the next set of experiments, we sought to examine the potential involvement of PKCε in invasiveness by assessing the ability of cells to migrate through Matrigel in a Boyden chamber (18) . It has been previously reported that PC3 and PC3-ML cells are highly invasive (25) . Notably, PC3-ML-KDε1 and PC3-ML-KDε2 cells showed a major impairment in invasiveness relative to parental PC3-ML cells and PC3-ML-NTC cells (Fig. 4a) . Similar results were observed in DU-145 cells (data not shown). To further establish a role of PKCε in PC3-ML invasiveness we used the PKCε inhibitor εV1-2, a Tat-fused permeable peptide that specifically prevents PKCε translocation to the membrane and therefore inhibits its activation (18, 34) . Consistent with results using PKCε RNAi, this inhibitor markedly reduced PC3-ML cell invasion through Matrigel relative to the control Tat peptide (Fig. 4b) . 
validated using a silencing approach, both by qPCR (Fig. 4d) and Western blot (Fig. 4e) . It has been recently established that IL-1β is up-regulated in prostate cancer cells; moreover, silencing IL-1β expression interferes with the bone metastatic potential of PC3-ML cells (26) . As our results suggest IL-1β as a PKCε target, we reasoned that inhibition of IL-1β signaling should also affect PC3-ML invasiveness. Indeed, incubation of PC3-ML with an anti-IL-1β blocking antibody significantly reduced invasion of PC3-ML cells through Matrigel (Fig. 4f) . Addition of IL-1β rescued the effect of PKCε knockdown on invasion in these cells (Fig. 4g) . This suggests that PKCε-mediated IL-1β production is important for PC3-ML cell invasiveness.
PKCε is required for transendothelial migration and growth of PC3-ML cells in a bone biomimetic microenvironment
The ability of cancer cells to migrate through the endothelial cell layer represents a key event in tumor metastasis. Prostate cancer cell extravasation to bone requires tethering to the bone marrow endothelium and transmigration (35) . To address the effect of PKCε depletion on migration through endothelial cells, we used an in vitro transendothelial assay (31).
Remarkably, PC3-ML-KDε1 and PC3-ML-KDε2 cells have a major deficiency in their ability
to transmigrate through a monolayer of endothelial cells (HUVEC) relative to parental PC3-ML or PC3-ML-NTC cells (Fig. 5a) . The reduced invasive capacity of PKCε-depleted cells through endothelial cells could be readily observed in 3D pictures taken by confocal microscopy, which show clear migration underneath the endothelial cells only for parental PC3 cells and PC3-ML-NTC cells but not for PKCε-depleted PC3-ML cells (Fig. 5b) . The impaired transmigratory properties of PKCε silenced PC3-ML cells is not due to weakened adhesion, as determined by the similar capacity of control and PKCε-silenced PC3-ML cells to attach to confluent monolayers of non-stimulated (Fig. 5c) were no significant differences in the ability of all PC3-ML cell lines to adhere to MG-63 osteoblast cells (Fig. 6a) , a reduced ability to grow under these conditions was observed for PC3-ML-KDε1 and PC3-ML-KDε2 cells (Fig. 6b) . 
DISCUSSION
The mechanisms implicated in prostate cancer initiation and progression have been extensively studied, and significant advances in our understanding of the genes and signaling pathways that contribute to the various steps of disease progression have been elucidated, particularly those concerning the growth of the primary tumor. Unfortunately, the mechanisms leading to metastatic dissemination of prostate cancer cells, particularly to the bone, remain poorly understood. In this study, we identified PKCε as a novel player in skeletal metastasis of prostate cancer cells. Our results clearly show that silencing the expression of PKCε from PC3-ML cells, a subline that metastasizes with high propensity to the bone, prevents the formation of skeletal metastatic foci upon inoculation into nude mice, thus reflecting the requirement of PKCε in key steps leading to prostate cancer cell colonization in the bone.
PKCε has been widely associated with the development of epithelial cancers, and has been originally described as an oncogenic kinase that is able to transform fibroblasts through the activation of the Ras-Raf1 signaling pathway and autocrine secretion of TGF-β (19, 36, 37) .
Numerous laboratories underscored important roles for PKCε in cell cycle progression and the control of cell survival mechanisms (2, 5, 6) . For example, forced expression of PKCε in LNCaP prostate cancer cells accelerates proliferation due to constitutive activation of the Erk cascade and protects cells against apoptotic stimuli (21, 22) . Our laboratory found that PKCε modulates Bad phosphorylation to protect LNCaP cells against phorbol ester-and TNFα-induced apoptosis (38) . In other cell models, such as lung cancer cells, PKCε regulates the expression of genes implicated in cell death and survival, and plays essential roles in anchorage-dependent and anchorage-independent growth (13) . PKCε overexpression is a signature of many cancer types, including breast, lung, and head and neck cancer (2, (7) (8) (9) (10) 12) . Several lines of evidence indicate that PKCε is frequently up-regulated in prostate cancer cell lines and tumor specimens, and is a predictive biomarker of prostate cancer; moreover, its expression correlates with aggressiveness and recurrence (10, 20, 21) . Notably, overexpression of PKCε in androgen-dependent LNCaP cells initiates tumor growth in intact and castrated nude mice, arguing for a potential role of this kinase in the progression to androgen independence (22) . Transgenic mice generated in our There is a growing body of evidence for the involvement of PKCε in cancer cell migration and invasion, as well as in the regulation of Rho GTPases that govern these processes, as we recently reported in lung cancer cells (18) . PKCε depletion or inhibition significantly impairs motility in a number of cancer cell models, namely lung, breast, and colon cancer (7, 18, 19, 39) . Strikingly, PKCε overexpression has been associated with elevated incidence of spontaneous and experimental metastases in mouse models. 
our studies did not reveal major defects in the capacity of PKCε-deficient PC3-ML cells to adhere to endothelial cells, a process that depends on multiple players such as the ligand Eselectin and integrins β1 and αvβ3 (35), we observed a major impairment in their ability to transmigrate through the endothelial layer. Although a detailed mechanistic analysis would be required to decipher how PKCε drives this transmigratory process, we speculate that MMPs regulated by PKCε may be involved in the activation/shedding of chemokines implicated in prostate cancer cell extravasation of prostate cancer cells, such as CX3CL1/fractalkine (41) .
A notable alteration that we identified in PKCε-depleted PC3-ML cells is a marked reduction in IL-1β expression. Although the mechanisms by which PKCε controls IL-1β expression are not known, it has been reported that in prostate cancer this kinase activates pathways such as NF-κB and Erk (23) 
COX-2 expression and PGE 2 production in bone marrow-derived mesenchymal stem cells (44) .
As COX2 is a PKCε effector gene in prostate cancer cells (24) 
